AU2020319732B2 - MHC class II molecules and methods of use thereof - Google Patents

MHC class II molecules and methods of use thereof

Info

Publication number
AU2020319732B2
AU2020319732B2 AU2020319732A AU2020319732A AU2020319732B2 AU 2020319732 B2 AU2020319732 B2 AU 2020319732B2 AU 2020319732 A AU2020319732 A AU 2020319732A AU 2020319732 A AU2020319732 A AU 2020319732A AU 2020319732 B2 AU2020319732 B2 AU 2020319732B2
Authority
AU
Australia
Prior art keywords
drb1
amino acid
seq
position corresponding
acid residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020319732A
Other languages
English (en)
Other versions
AU2020319732A1 (en
Inventor
Tingxi GUO
Naoto Hirano
Kenji SUGATA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University Health Network
Original Assignee
University Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Health Network filed Critical University Health Network
Publication of AU2020319732A1 publication Critical patent/AU2020319732A1/en
Application granted granted Critical
Publication of AU2020319732B2 publication Critical patent/AU2020319732B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
AU2020319732A 2019-07-30 2020-07-29 MHC class II molecules and methods of use thereof Active AU2020319732B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962880509P 2019-07-30 2019-07-30
US62/880,509 2019-07-30
US202063029115P 2020-05-22 2020-05-22
US63/029,115 2020-05-22
PCT/IB2020/057174 WO2021019474A1 (en) 2019-07-30 2020-07-29 Mhc class ii molecules and methods of use thereof

Publications (2)

Publication Number Publication Date
AU2020319732A1 AU2020319732A1 (en) 2022-03-03
AU2020319732B2 true AU2020319732B2 (en) 2026-07-09

Family

ID=74230294

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020319732A Active AU2020319732B2 (en) 2019-07-30 2020-07-29 MHC class II molecules and methods of use thereof

Country Status (12)

Country Link
US (1) US20220281949A1 (cg-RX-API-DMAC7.html)
EP (1) EP4004033A4 (cg-RX-API-DMAC7.html)
JP (1) JP7811541B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220052944A (cg-RX-API-DMAC7.html)
CN (1) CN114502580B (cg-RX-API-DMAC7.html)
AU (1) AU2020319732B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022001702A2 (cg-RX-API-DMAC7.html)
CA (1) CA3146296A1 (cg-RX-API-DMAC7.html)
IL (1) IL290231A (cg-RX-API-DMAC7.html)
MX (1) MX2022001211A (cg-RX-API-DMAC7.html)
TW (1) TW202118781A (cg-RX-API-DMAC7.html)
WO (1) WO2021019474A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020231693A1 (en) 2019-03-04 2021-09-30 University Health Network T cell receptors and methods of use thereof
TWI881991B (zh) * 2019-07-30 2025-05-01 大學健康網絡 Ii類mhc分子及其使用方法
TW202116797A (zh) 2019-07-30 2021-05-01 大學健康網絡 Ii類mhc分子及其使用方法
CN118662607B (zh) * 2023-03-15 2026-07-07 中国科学院上海药物研究所 抑制过激炎性反应的蛋白及其应用
US20250074966A1 (en) * 2023-08-31 2025-03-06 Adaptive Biotechnologies Corporation Agents and methods for preventing or inhibiting adaptive immune responses associated with multiple sclerosis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601801B2 (en) * 2003-07-11 2009-10-13 Dainippon Sumitomo Pharma Co., Ltd. HLA-A24 binding cancer antigen peptide derived from livin
US20060228758A1 (en) * 2004-09-13 2006-10-12 Xencor, Inc. Analysis of MHC-peptide binding interactions
GB0911566D0 (en) * 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9738724B2 (en) * 2012-06-08 2017-08-22 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
US9717758B2 (en) * 2013-05-17 2017-08-01 University Of Massachusetts High-affinity DMF5 T cell receptor (TCR) variants
WO2016135363A1 (es) * 2015-02-23 2016-09-01 Servicio Andaluz De Salud Método de obtención de datos útiles para predecir o pronosticar la transmisión vertical, la cronificación y/o el aclaramiento del virus de la hepatitis c
MX2018006789A (es) * 2015-12-03 2019-02-13 Juno Therapeutics Inc Receptores quimericos modificados y composiciones y metodos relacionados.
KR20180087430A (ko) * 2015-12-17 2018-08-01 얀센 바이오테크 인코포레이티드 Hla-dr에 특이적으로 결합하는 항체 및 이의 용도
GB201604492D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
US12187781B2 (en) * 2018-08-01 2025-01-07 Regents Of The University Of Minnesota Co-receptor affinity enhanced major histocompatibility class II molecules

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE Protein 11 February 2018 (2018-02-11), "MHC class II antigen, partial [Homo sapiens]", XP055789378, retrieved from NCBI *
GenBank Accession number XP_023576849 (HLA class II histocompatibility antigen, DP beta 1 chain-like [Octodon degus], 24 January 2018). (Year: 2018) *
UniProt Acession No: A0A5K1UW69 MACMU Rhesus Macaque Genome Sequencing and Analysis Consortium, GIBBS, RA et al., Evolutionary and Biomedical Insights from the Rhesus Macaque Genome, Science, 316(5822), pages 222-234, 2007 *
ZHU, Z. F., et al., 1991, "Mhc-DRB Genes of the Pigtail Macaque (Macaca nemestrina): Implications for the Evolution of Human DRB Genes", Molecular Biology and Evolution, 8(5), pages 563-578 *

Also Published As

Publication number Publication date
EP4004033A4 (en) 2023-12-06
US20220281949A1 (en) 2022-09-08
BR112022001702A2 (pt) 2022-06-21
TW202118781A (zh) 2021-05-16
CA3146296A1 (en) 2021-02-04
JP2022542448A (ja) 2022-10-03
EP4004033A1 (en) 2022-06-01
WO2021019474A1 (en) 2021-02-04
CN114502580B (zh) 2025-10-17
IL290231A (en) 2022-03-01
KR20220052944A (ko) 2022-04-28
MX2022001211A (es) 2022-05-03
JP7811541B2 (ja) 2026-02-05
CN114502580A (zh) 2022-05-13
AU2020319732A1 (en) 2022-03-03